FDA-cleared profile

Second Opinion

Pearl Inc. · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Second Opinion is a concurrent-reading aid for dental professionals reviewing bitewing and periapical radiographs of permanent teeth in patients aged 12 years and older.

Clinical role
Concurrent second-reader support for labeled dental radiographic findings.
Images and patients
X-ray/Radiography · Permanent teeth; caries, restoration margins, calculus, periapical radiolucency, and dental restorations
Key limitation
Keep in mind: Use is limited to the labeled radiograph types, permanent teeth, and patients aged 12 years and older. The output is a second opinion and does not replace complete dental examination or professional judgment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Second Opinion is a concurrent-reading aid for dental professionals reviewing bitewing and periapical radiographs of permanent teeth in patients aged 12 years and older.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Permanent teeth; caries, restoration margins, calculus, periapical radiolucency, and dental restorations Input: Bitewing and periapical radiographs of permanent teeth.
  • Who uses it?Intended users: Dental health professionals.
  • What does the software produce?Output: Graphical markings and metadata for caries, restoration-margin discrepancy, calculus, periapical radiolucency, crowns, fillings, root canals, bridges, and implants.
  • What is its most important limitation?Key limitation: Use is limited to the labeled radiograph types, permanent teeth, and patients aged 12 years and older. The output is a second opinion and does not replace complete dental examination or professional judgment.

Clinical takeaway. Clinical role: Second Opinion is a concurrent-reading aid for dental professionals reviewing bitewing and periapical radiographs of permanent teeth in patients aged 12 years and older.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports retrospective, multi-site standalone and MRMC studies on 2,010 images, with consensus ground truth from at least three of four GT readers. Standalone wAFROC-FOM 95% CI at Jaccard Index 0.4 was (0.73, 0.79) caries, (0.71, 0.78) MD, (0.78, 0.85) calculus and (0.75,0.84) PR. Twenty-five MRMC readers each read 2,010 images (1,005 unaided, 1,005 aided); aided performance improved significantly for all four pathologies, with caries wAFROC-FOM 0.740 unaided vs 0.758 aided (P=0.0062). Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Second Opinion is a concurrent-reading aid for dental professionals reviewing bitewing and periapical radiographs of permanent teeth in patients aged 12 years and older.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Concurrent second-reader support for labeled dental radiographic findings.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Bitewing and periapical radiographs of permanent teeth.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Graphical markings and metadata for caries, restoration-margin discrepancy, calculus, periapical radiolucency, crowns, fillings, root canals, bridges, and implants.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Dental offices and clinics.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Dental health professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Use is limited to the labeled radiograph types, permanent teeth, and patients aged 12 years and older. The output is a second opinion and does not replace complete dental examination or professional judgment.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports retrospective, multi-site standalone and MRMC studies on 2,010 images, with consensus ground truth from at least three of four GT readers. Standalone wAFROC-FOM 95% CI at Jaccard Index 0.4 was (0.73, 0.79) caries, (0.71, 0.78) MD, (0.78, 0.85) calculus and (0.75,0.84) PR. Twenty-five MRMC readers each read 2,010 images (1,005 unaided, 1,005 aided); aided performance improved significantly for all four pathologies, with caries wAFROC-FOM 0.740 unaided vs 0.758 aided (P=0.0062). Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The studies were conducted as retrospective, unblinded open-label, multi-site trials that produced clinically useful information on the potential application of this device in a dental office setting. 2,010 images reviewed by all four GT readers were used for the standalone and MRMC studies:" … "The ground truth (GT) was assessed using the consensus approach (based on agreement among at least three out of". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports retrospective, multi-site standalone and MRMC studies on 2,010 images, with consensus ground truth from at least three of four GT readers. Standalone wAFROC-FOM 95% CI at Jaccard Index 0.4 was (0.73, 0.79) caries, (0.71, 0.78) MD, (0.78, 0.85) calculus and (0.75,0.84) PR. Twenty-five MRMC readers each read 2,010 images (1,005 unaided, 1,005 aided); aided performance improved significantly for all four pathologies, with caries wAFROC-FOM 0.740 unaided vs 0.758 aided (P=0.0062). Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The studies were conducted as retrospective, unblinded open-label, multi-site trials that produced clinically useful information on the potential application of this device in a dental office setting. 2,010 images reviewed by all four GT readers were used for the standalone and MRMC studies:" … "The ground truth (GT) was assessed using the consensus approach (based on agreement among at least three out of". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
76.39%; 0.9%; 11.7%; 68%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K210365 FDA evidence package for Second Opinion

  • DesignFDA 510(k) decision evidence and product verification for the exact submission.
  • PopulationPermanent teeth; caries, restoration margins, calculus, periapical radiolucency, and dental restorations
  • Scopeexact submission
  • Tested versionSecond Opinion
  • IndependenceSponsor or vendor study

K210365

FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K210365 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Bitewing and periapical radiographs of permanent teeth.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K210365: Second Opinion

  2. Routing

    Source context, not route validation: The FDA package describes a clinician-office client, cloud processing of radiographs, and return of findings and metadata to the interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K210365: Second Opinion

  3. AI processing

    Source context, not route validation: The FDA package describes cloud-based processing with a client in the clinician office; current hosting, contracts, security, availability, and local configuration remain unknown.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K210365: Second Opinion

  4. Returned objects

    Source context, not route validation: Graphical markings and metadata for caries, restoration-margin discrepancy, calculus, periapical radiolucency, crowns, fillings, root canals, bridges, and implants.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K210365: Second Opinion

  5. Viewer/worklist/report

    Unresolved route: Graphical markings and metadata for caries, restoration-margin discrepancy, calculus, periapical radiolucency, crowns, fillings, root canals, bridges, and implants.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K210365: Second Opinion

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes cloud-based processing with a client in the clinician office; current hosting, contracts, security, availability, and local configuration remain unknown.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
The FDA package describes a clinician-office client, cloud processing of radiographs, and return of findings and metadata to the interface.
  • Exact FDA submission
  • Checked 2026-09-04
Security
Pearl's data protection page states HIPAA-compliant logging of data access, TLS 1.2 in transit and AES-256 encryption at rest, with static code analysis and vulnerability scanning. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Training
Use by dental health professionals. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K210365.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K210365.

exact submission · checked 2026-09-04

Deployment boundary

The FDA package describes cloud-based processing with a client in the clinician office; current hosting, contracts, security, availability, and local configuration remain unknown.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA package describes a clinician-office client, cloud processing of radiographs, and return of findings and metadata to the interface.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K210365.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K210365
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Permanent teeth; caries, restoration margins, calculus, periapical radiolucency, and dental restorations
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-03-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

No evidence was promoted. Every record uses second opinion generically or concerns an unrelated intervention; none identifies Pearl Second Opinion, a tested product version, or K210365. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K210365: Second Opinion

    U.S. Food and Drug Administration - Published 2022-03-04 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Second Opinion model card (K210365)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. Pearl Data Protection

    Pearl - Accessed 2026-10-25

    Scope: security

Research history

  1. K210365 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253172

MediAI-OA

Crescom Co., Ltd.

Authorized purpose: Assist trained professionals in assessing radiographic knee osteoarthritis and its sclerosis, joint-space-narrowing, and osteophyte features on standing fixed-flexion knee radiographs.

Modality
X-ray/Radiography
Anatomy
Knee joint
Decision
2026-06-15
FDA-cleared K253930

Overjet Iris Intelligent Imaging System

Overjet, Inc.

Authorized purpose: Overjet Iris is a web-based dental PACS for storing, viewing, and supporting image-quality review of two-dimensional intraoral radiographs, panoramic images, and color photographs.

Modality
X-ray/Radiography
Anatomy
Teeth and maxillofacial anatomy
Decision
2026-04-10
FDA-cleared K250525

Second Opinion® Panoramic

Pearl, Inc.

Authorized purpose: Second Opinion Panoramic is an automated image-processing aid that identifies and marks regions of interest for caries, periapical radiolucency, and impacted third molars on panoramic radiographs of permanent teeth in patients aged 16 years and older.

Modality
X-ray/Radiography
Anatomy
Permanent teeth; caries, periapical radiolucency, and impacted third molars
Decision
2025-11-14
FDA-cleared K251002

Videa Dental AI

VideaHealth Inc.

Authorized purpose: Analyzes bitewing, periapical, and panoramic intraoral radiographs from patients aged 3 years and older to identify and localize specified suspected dental findings, historical treatments, and normal anatomy; diagnostic use remains with trained dental professionals.

Modality
X-ray/Radiography
Anatomy
Dental/Maxillofacial
Decision
2025-09-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history